特定非営利活動法人
日本免疫学会
Japanese Society for Immunology

第41回日本免疫学会学術集会

2012 Annual Meeting of the Japanese Society for Immunology

クリニカルセミナー／Clinical Seminar

Immunotherapy of cancer through the adoptive transfer of gene-modified T lymphocytes : The UPenn experience

座長 Chair

東京大学医学部附属病院
免疫細胞治療学（メディネット）講座 特任准教授

垣見 和宏 先生

Project Associate Professor, Department of Immunotherapeutics,
The University of Tokyo Hospital

Kazuhiro Kakimi, M.D., Ph.D.

演者 Speaker

Perelman school of medicine,
University of Pennsylvania

Michael Kalos, Ph. D.

2012.12.7 FRI

神戸国際会議場 3階 C会場
Kobe International Conference Center, 3rd floor, Room C

12:00 ~ 13:00

お弁当との引き換えにはチケットが必要です。

Ticket Place: 神戸国際会議場 3階 Kobe International Conference Center 3rd floor Time: 7:30~11:10

共催：特定非営利活動法人 日本免疫学会 / 株式会社 メディネット
Co-sponsored by Japanese Society for Immunology and MEDINET Co., Ltd.

IMMUNOTHERAPY OF CANCER THROUGH THE ADOPTIVE TRANSFER OF GENE-MODIFIED T LYMPHOCYTES: THE UPENN EXPERIENCE

Michael Kalos, Ph.D.

Perelman School of Medicine, University of Pennsylvania

Harnessing the potential of T cells to target and eliminate cancer has been a long-standing objective of immunotherapy. The adoptive transfer of ex-vivo expanded T cells engineered to potently recognize tumors is one promising conceptual approach that has the potential to overcome limitations associated with central and peripheral immune tolerance. At the University of Pennsylvania our programmatic efforts have focused on engineering T cells to target cancers via chimeric antigen receptors (CAR) and affinity-enhanced T cell receptors (TCR), using both stable transient gene delivery approaches.

This presentation will focus on a discussion of data from current and ongoing clinical trials to evaluate the safety, feasibility, and preliminary efficacy of our programmatic approaches to target cancer using engineered T lymphocytes. We will focus principally on published and emerging data from our ongoing clinical efforts to target B cell leukemias using T cells redirected against CD19 via CAR that contain 4-1-BB and TCR zeta signaling domains (CART19 cells), a setting where we have observed robust and sustained complete responses in patients with advanced and treatment refractive disease. We will additionally discuss data from early-stage clinical trials to target other hematological and solid malignancies using both CAR and TCR-based approaches.

(2012 Annual Meeting of the Japanese Society for Immunology, Abstract)

Chair Kazuhiro Kakimi, M.D., Ph.D.

EDUCATION and PROFESSIONAL EXPERIENCE

1983-1988	M.D., Kyoto University, Kyoto, Japan
1988-1991	Resident, Department of Internal Medicine, Kyoto University Hospital, Kyoto, Japan
1991-1995	Ph.D. Course, Field of Medical Science, Kyoto University
1995 -1998	Assistant Professor, Department of Bioregulation School of Medicine, Mie University
1996-2001	Research Associate, Department of Molecular and Experimental Medicine, The Scripps Research Institute
2001-2004	Assistant Professor, Department of Internal Medicine, Tokyo Medical University
2001-Current	Adjunct Assistant Professor, Department of Molecular and Experimental Medicine The Scripps Research Institute
2004-Current	Project Associate Professor, Department of Immunotherapeutics, The University of Tokyo Hospital

Speaker Michael Kalos, Ph.D.

Education

1983	B.S. University of Minnesota (Biochemistry)
1990	Ph.D. University of Minnesota Medical School (Microbiology)

Postgraduate Training and Fellowship Appointments

1990-1994	Division of Basic Sciences, Fred Hutchinson Cancer Research Center
1994-1997	Division of Clinical Research, Fred Hutchinson Cancer Research Center

Faculty Appointments

2004-2006	Associate Professor in Residence, Division of Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA
2006-2008	Associate Professor in Residence, Division of Cancer Immunotherapeutics and Tumor Immunology, City of Hope National Medical Center, Duarte, CA
2009-Current	Adjunct Associate Professor, Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA

Hospital and Administrative Appointments

2004-2008	Director, Clinical Immunobiology Correlative Studies Laboratory, City of Hope National Medical Center
2005-2008	Co-Director, Core E, City of Hope Lymphoma SPORE grant
2008-Current	Director, Translational and Correlative Science Laboratory, University of Pennsylvania School of Medicine

Other Appointments

1998-2000	Staff Scientist, Corixa Corporation, Seattle, WA
2000-2004	Senior Staff Scientist, Corixa Corporation, Seattle, WA
2004-2007	Associate Member, City of Hope Comprehensive Cancer Center, City of Hope National Medical Center, Duarte, CA
2009-Current	Member Institute for Translational Medicine and Therapeutics, University of Pennsylvania
2009-Current	Member, Abramson Cancer Center, University of Pennsylvania School of Medicine
2009-Current	Associate Member, Abramson Family Cancer Research Institute, University of Pennsylvania School of Medicine